【市场】17个国谈药拟进院，独家品种霸屏

米内网02-25

精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。此次拟进院的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2614554709?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-25 16:07","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2614554709","market":"us","top_or_hot":-1,"title":"【市场】17个国谈药拟进院，独家品种霸屏","media":"米内网","content":"<div>\n<p>精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。此次拟进院的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【市场】17个国谈药拟进院，独家品种霸屏</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【市场】17个国谈药拟进院，独家品种霸屏\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-25 16:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。此次拟进院的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600276","symbol_name":"恒瑞医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","article_id":"2614554709","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614554709","pubTimestamp":1772006826,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","01276":"恒瑞医药","NVOX":"2倍做多NVO ETF-Defiance","BK4599":"减肥药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVO":"诺和诺德","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","002793":"罗欣药业","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","002653":"海思科","BK4585":"ETF&股票定投概念","NVOH":"Novo Nordisk A/S B Shares ADRhedged","NVS":"诺华","BK4532":"文艺复兴科技持仓"},"translate_title":"[Market] 17 national drugs plan to enter the hospital, and exclusive varieties dominate the screen","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.61,"002653":1.67,"NVS":1.64,"01276":1.61,"NVOX":0.6,"NVOH":0.6,"NVO":0.9,"002793":1.67},"content_text":"精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。此次拟进院的新药在剂型上较为丰富，包括普通片剂、胶囊剂、注射剂、滴眼剂等，其中以注射剂、普通片剂为主。独家品种（含独家剂型）占比超八成，包括恒瑞医药的富马酸泰吉利定注射液、海思科的环泊酚注射液及安瑞克芬注射液、南京正大天晴的芦比前列酮软胶囊等国产品牌，以及诺和诺德的依柯胰岛素注射液、礼来的替尔泊肽注射液、诺华的英克司兰钠注射液等进口品牌。拟引入药品目录（2026年第一批）注：标*为独家品种来源：成都市第六人民医院，米内网数据库海思科开发的环泊酚注射液最早于2020年12月获批上市，为国内获批的首个1.1类静脉麻醉药，目前已有3个适应症纳入国家医保乙类目录。米内网数据显示，该药近年来在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端迅速放量，2025年前三季度销售额接近13亿元，同比增长约64%。近年来中国公立医疗机构终端环泊酚注射液销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局芦比前列酮软胶囊（南京正大天晴独家）、替戈拉生片（罗欣药业独家）、奈妥匹坦帕洛诺司琼胶囊、英克司兰钠注射液（诺华独家）等品种2025年前三季度在中国公立医疗机构终端的销售额增速均达三位数。罗欣药业开发的替戈拉生片最早于2022年4月获批上市，为国内获批的首个新型钾离子竞争性酸阻滞剂(P-CAB)类药物，目前已有3个适应症纳入国家医保乙类目录。该药近年来在中国公立医疗机构终端的销售额均以三位数的增速持续增长，2025年前三季度超过6亿元，远超2024年全年水平。近年来中国公立医疗机构终端替戈拉生片销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614554709","isCrawlerRequest":true}